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ABSTRACT 
 
Bioavailability and pharmacokinetics of two commercially available preparations of norfloxacin i.e. A 
(imported) and B (locally prepared) were determined in six healthy female goats after single intramuscular 
administration @ 5 mg/kg b.wt following crossover study design. The blood samples collected at 0.25, 0.5, 
0.75, 1, 2, 3, 4, 6, 8 and 12 hours postmedication were also analysed for drug concentration by 
microbiological assay. Results revealed that preparation A showed higher (p<0.05) plasma drug levels than 
the preparation B at 1, 3, 6 and 8 hours after medication. Among bioavailability parameters AUC (µg.h/ml) 
and relative bioavailability (F%) were higher for preparation A than the preparation B, while other 
parameters did not differ between the two preparations. Similarly, various pharmacokinetic parameters did 
not show any statistical difference between preparation A and B. The study revealed comparable 
elimination kinetics but different bioavailability of two commercial preparations of norfloxacin. It is 
concluded from the study that for optimal dosage regimen of drugs, the bioequivalence studies and kinetic 
behavior of the drugs are of paramount importance. 
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INTRODUCTION 
 
Bioavailability and pharmacokinetics of drugs 
influence their therapeutic, clinical and toxic effects. 
Further, these help in monitoring the course of therapy. 
The variation in the bioavailability of different 
formulations of the same drug given at the same 
strength and in the same dosage form poses a special 
challenge to health care professionals, making these 
issues very relevant to pharmacists. 
Norfloxacin is a synthetic antibiotic belonging of 
the flouroquinolones class and is usually prescribed for 
the treatment of urinary tract infections. Flouro-
quinolones are gaining popularity as important 
antibacterial agents in veterinary practice because of 
their broad antimicrobial activity (Park et al., 1998). 
Quinolones are active against gram negative and gram-
positive bacteria in vitro (Wolfson and Hooper, 1985), 
as well as trimethoprim/sulfonamide resistant microbes 
(Perheim et al., 1987). In addition, these antimicrobials 
are also active against Mycoplasma (Brown, 1996). 
Moreover, no plasmid resistance has been demonstrated 
and flouroquinolones have a favorable margin of safety 
(Bahri and Blouin, 1991). 
 Norfloxacin is available in the market in different 
dosage forms and formulations. The method of 
manufacture and final formulation of the drug can 
markedly affect its bioavailability and pharmaco-
kinetics. Different pharmaceutical companies especially 
multinational ones claim the superiority of their 
products with better bioavailability and 
pharmacokinetics. These claims, as well as increasing 
use of norfloxacin  in the modern human and veterinary  
 
practices, necessitate the evaluation of bioavailability 
and pharmacokinetics of these preparations. Therefore, 
the present study was designed to investigate the 
bioavailability and pharmacokinetics of two 
commercial preparations of norfloxacin. 
 
MATERIALS AND METHODS 
 
Experimental animals and drug 
The present study was conducted on six adult 
healthy female goats maintained under similar 
managemental conditions at animal shed, Department 
of Clinical Medicine and Surgery, University of 
Agriculture, Faisalabad, Pakistan. The average body 
weight of animals was 19 kg (range 15-30 kg). Two 
commercial injectable preparations of norfloxacin i.e. A 
(Doctorgin 10% inj., Microbiological Lab., Korea) and 
B (Norfloxacin-50, 5% inj., Kakhasian Pharmaceutics, 
Pakistan.) were used. After restraining the animals, a 
single dose of preparation A (5 mg/kg b.wt) was given 
intramuscularly. After a wash out period of 7 days, 
experimental goats were given preparation B at a dose 
rate of 5mg/kg b.wt I/M following crossover design. 
 
Collection of blood samples 
Jugular blood samples were collected from 
experimental goats in heparinized glass centrifuge tubes 
before and 0.25, 0.50, 0.75, 1, 2, 3, 4, 6, 8 and  12 hours 
after medication. Plasma was separated after 
centrifugation at 3000 rpm for 15 minutes and stored at 
-4 C° until analysis. 
  14Pakistan Vet. J., 2006, 26(1): 14-16.  15
Analytical method 
Norfloxacin concentrations in plasma were 
determined by microbiological assay according to disc 
agar diffusion method, as described by Arret et al. 
(1971) and Shungu et al. (1983), using Bacillus 
substilis as a sensitive organism. Bioavailability and 
kinetic parameters i.e. area under curve (AUC), absorption 
rate constant (Kab), absorption half life (T1/2ab), peak 
concentration (Cmax), time to peak concentration (Tmax), 
relative bioavailability (F%), total body clearance (ClB), 
volume of distribution (Vd), distribution half life (T1/2α), 
elimination half life (T1/2β), elimination rate constant (Kel), 
drug transfer rate constant (K12) and  (K21) and mean 
residance time (MRT) were calculated by using computer 
software MW\Pharm Version 3.02. 
 
Statistical analysis  
Mean values (± SD) for the concentrations, 
bioavialability and pharmacokinetics of two 
preparations of norfloxacine were computed. The data 
were further subjected to parametric comparison 
between two groups using Mini-tab computer 
programme (descriptive statistics t-test). 
 
RESULTS AND DISCUSSION 
 
The mean (± SD) norfloxacin plasma concentrations at 
various time intervals after intramuscular  administration of 
equal single doses of two commercial  norfloxacin 
preparations A and B are shown in Table 1 and Fig. 1. The 
values of bioavailability parameters, which describe the rate 
and extent of absorption of a drug from the site of 
administration into the blood, are shown in the Table 2. The 
values of pharmacokinetic parameters which describe 
disposition of the drug in the body are given in Table 3. 
Following an intramuscular administration, the 
preparation A gave higher drug plasma levels than 
preparation B. However, these plasma levels were only 
significantly higher at 1, 3, 6 and 8 hours post 
medication. The mean (± SD) area under concentration  
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Fig. 1:  Mean plasma concentrations of preparations 
A and B versus time after I/M adminis-
trations (5 mg/kg) in goats. 
 
versus time curve (AUC) of preparation A (7.57 ± 1.10 
µg.h/ml) was significantly higher (P<0.01) than 5. 05 ± 
1.50 µg.h/ml for preparation B. The value of F (%) was 
also significantly higher (P<0.05) for preparation A 
than preparation B. However, other parameters of 
bioavailability did not differ between the two 
preparations. 
It may be revealed from the bioavailability 
parameters that the rate of absorption of norfloxacin 
from preparation A was higher than that from 
preparation B. The preparation A also gave more than 
100% relative bioavailability as compared to 66.90% 
for preparation B. The higher values of relative 
bioavailability and extent of absorption of the drug 
indicates that preparation A has different bioavailability 
from preparations B. Such variations could be attributed 
to pharmaceutical factors involved during production of 
the two preparations. 
The mean (± SD) values of various pharmacokinetics 
parameters given in the Table 3 did not differ significantly 
between two preparations of norfloxacin. The apparent 
volume of distribution (Vd) relates the drug concentration 
in plasma to the total amount of drug in the body after the 
distribution equilibrium has been attained. The mean 
values for Vd for preparation A and B were 3.37 ± 0.62 
and 7.43 ± 4.86 L/kg, respectively. 
Table 1: Mean (±SD) plasma concentrations 
(µg/ml) of two preparations of 
norfloxacin after I/M administration 
(5 mg/kg) in goats  
Time 
(hrs)  Preparation A  Preparation B 
0.25  1.16 ± 0.47  1.03   ± 0.40
 NS 
0.50  1.60 ± 0.46   1.60  ± 0.52
 NS 
0.75  2.70 ± 0.25  2.31  ± 0.83
 NS 
1.00  2.30 ± 0.60  1.74  ± 0.550* 
2.00  1.33 ± 0.28  1.17  ± 0.02
 NS 
3.00  1.01 ± 0.19  0.55 ± 0.510* 
4.00  0.73 ± 0.21  0.35 ± 0.13
 NS 
6.00  0.49 ± 0.51  0.18  ± 0.08** 
8.00  0.33 ± 0.43  0.12  ± 0.05** 
NS = Non significant, 
* = Significant at P<0.05, 
** = Significant at P<0.01. 
Body clearance (ClB) represents the sum of 
metabolic and excretery processes and is the volume of 
blood completely cleared of a drug in a unit time. The 
mean ClB values for preparation A and preparation B 
were 0.55 ± 0.20 and 0.96 ± 0.36 L/h/kg, respectively.  
The mean values of elimination half life (T½β) for 
preparations A and B were 4.60 ± 1.63 and 5.24 ± 1.98 
hrs, respectively. However, the half life of the drug 
recorded in the present study is longer than 3.5 hrs 
reported in dogs (Brown et al., 1990) and shorter than 
9.25 hrs reported in man (Seth et al., 1995) 
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For optimal therapeutic levels of antibacterial 
agents in blood, the bioavailability and drug disposition 
studies play a pivatal role. This study revealed 
comparable elimination kinetics but different 
bioavailability of two commercial preparations of 
norfloxacin in goats. These results signify the 
importance of the bioequivolence studies of different 
commercial preparations of the same drug prepared by 
different companies. Moreover, the pharmacokinetic 
parameters of norfloxacin determined in goats were 
different from those found in other animals such as 
sheep, broilers and dogs (Kivisto et al., 1992; Song and 
Chen, 1995; Albarellos et al., 1996; Gonzalez et al., 
1997). 
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